Pivotal roles of monocytes/macrophages in stroke

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Chiba, Tsuyoshi ^a   Umegaki, Keizo ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ANTITHROMBOCYTIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; ROSIGLITAZONE; STATIN (PROTEIN); TERUTROBAN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; CELL ACTIVATION; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; DISEASE EXACERBATION; ENDOTHELIUM CELL; HEART INFARCTION; HYPERTENSION; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MICROGLIA; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALT LOADING; ANIMAL; CYTOLOGY; HUMAN; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; INFLAMMATION; MACROPHAGES; MICROGLIA; MONOCYTES; STROKE;

EID: 84874519838     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/759103     Document Type: Review

References (128)

1. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C. J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y., Heart disease and stroke statistics-2007 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 115 5 e69 e171 2-s2.0-33846857559 10.1161/CIRCULATIONAHA.106.179918 (Pubitemid 46226160)
2. Goldstein L. B., Bushnell C. D., Adams R. J., Guidelines for the primary prevention of stroke: a Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2011 42 2 517 584 10.1161/STR.0b013e3181fcb238
3. Blake G. J., Ridker P. M., Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine 2002 252 4 283 294 2-s2.0-0036035527 10.1046/j.1365-2796.2002.01019.x (Pubitemid 35253696)
4. Fassbender K., Bertsch T., Mielke O., Mühlhauser; F., Hennerici M., Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 1999 30 8 1647 1650 2-s2.0-0032788005 (Pubitemid 29379618)
5. Sánchez-Moreno C., Dashe J. F., Scott T., Thaler D., Folstein M. F., Martin A., Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004 35 1 163 168 2-s2.0-0347356516 10.1161/01.STR.0000105391.62306.2E (Pubitemid 38057613)
6. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., Petrek M., Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators of Inflammation 2005 2005 3 175 179 2-s2.0-25644437697 10.1155/MI.2005.175 (Pubitemid 41381527)
7. Prentice R. L., Szatrowski T. P., Kato H., Mason M. W., Leukocyte counts and cerebrovascular disease. Journal of Chronic Diseases 1982 35 9 703 714 2-s2.0-0019985742 (Pubitemid 12042344)
8. Fava M., Leukocytes and the risk of ischemic diseases. JAMA 1987 258 7 907 908 2-s2.0-0023661790
9. Gillum R. F., Ingram D. D., Makuc D. M., White blood cell count and stroke incidence and death: the NHANES I epidemiologic follow-up study. American Journal of Epidemiology 1994 139 9 894 902 2-s2.0-0028198404 (Pubitemid 24138392)
10. Grau A. J., Boddy A. W., Dukovic D. A., Buggle F., Lichy C., Brandt T., Hacke W., Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004 35 5 1147 1152 2-s2.0-2142716833 10.1161/01.STR.0000124122. 71702.64 (Pubitemid 38543534)
11. Blann A. D., Tse W., Maxwell S. J. R., Waite M. A., Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. Journal of Hypertension 1994 12 8 925 928 2-s2.0-0028106054 (Pubitemid 24283376)
12. Desouza C. A., Dengel D. R., Macko R. F., Cox K., Seals D. R., Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. American Journal of Hypertension 1997 10 12 1335 1341 2-s2.0-0031425589 10.1016/S0895-7061(97)00268-9 (Pubitemid 28078736)
13. Madej A., Okopień B., Kowalski J., Haberka M., Herman Z. S., Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacological Reports 2005 57 6 878 881 2-s2.0-33645679314
14. Newby A. C., Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 12 2108 2114 2-s2.0-57549112353 10.1161/ATVBAHA.108.173898
15. Ross R., Atherosclerosis-an inflammatory disease. The New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
16. Dollery C. M., Libby P., Atherosclerosis and proteinase activation. Cardiovascular Research 2006 69 3 625 635 2-s2.0-31344469271 10.1016/j.cardiores.2005.11.003 (Pubitemid 43139725)
17. Bar-Or A., Nuttall R. K., Duddy M., Alter A., Kim H. J., Ifergan I., Pennington C. J., Bourgoin P., Edwards D. R., Yong V. W., Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003 126 12 2738 2749 2-s2.0-0344443218 10.1093/brain/awg285 (Pubitemid 37463092)
18. Newby A. C., Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiological Reviews 2005 85 1 1 31 2-s2.0-12844286997 10.1152/physrev.00048.2003 (Pubitemid 40171256)
19. Johnson J. L., Sala-Newby G. B., Ismail Y., Aguilera C. M., Newby A. C., Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 9 1647 1653 2-s2.0-51649101109 10.1161/ATVBAHA.108.170548
20. Newby A. C., Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Current Opinion in Lipidology 2006 17 5 556 561 2-s2.0-33748550024 10.1097/01.mol.0000245262.48258.b4 (Pubitemid 44372687)
21. Schilling M., Besselmann M., Leonhard C., Mueller M., Ringelstein E. B., Kiefer R., Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Experimental Neurology 2003 183 1 25 33 2-s2.0-0042190147 10.1016/S0014-4886(03)00082-7 (Pubitemid 37075853)
22. Tanaka R., Komine-Kobayashi M., Mochizuki H., Yamada M., Furuya T., Migita M., Shimada T., Mizuno Y., Urabe T., Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience 2003 117 3 531 539 2-s2.0-0037475144 10.1016/S0306-4522(02)00954-5 (Pubitemid 36263149)
23. Nakajima K., Kohsaka S., Microglia: activation and their significance in the central nervous system. Journal of Biochemistry 2001 130 2 169 175 2-s2.0-0034866550 (Pubitemid 32785862)
24. Banati R. B., Gehrmann J., Schubert P., Kreutzberg G. W., Cytotoxicity of microglia. GLIA 1993 7 1 111 118 2-s2.0-0027351431
25. Barone F. C., Arvin B., White R. F., Miller A., Webb C. L., Willette R. N., Lysko P. G., Feuerstein G. Z., Tumor necrosis factor- α: a mediator of focal ischemic brain injury. Stroke 1997 28 6 1233 1244 2-s2.0-0030976856 (Pubitemid 27248902)
26. Rothwell N., Allan S., Toulmond S., The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. The Journal of Clinical Investigation 1997 100 11 2648 2652 2-s2.0-0031438499 (Pubitemid 28007530)
27. Schilling M., Besselmann M., Müller M., Strecker J. K., Ringelstein E. B., Kiefer R., Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Experimental Neurology 2005 196 2 290 297 2-s2.0-27744561356 10.1016/j.expneurol.2005.08.004 (Pubitemid 41607817)
28. Schilling M., Strecker J. K., Schäbitz W. R., Ringelstein E. B., Kiefer R., Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience 2009 161 3 806 812 2-s2.0-65749106380 10.1016/j.neuroscience.2009.04.025
29. Petry K. G., Boiziau C., Dousset V., Brochet B., Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics 2007 4 3 434 442 2-s2.0-34250773901 10.1016/j.nurt.2007.05.005 (Pubitemid 46962415)
30. Yamori Y., Predictive and preventive pathology of cardiovascular diseases. Acta Pathologica Japonica 1989 39 11 683 705 2-s2.0-0024797045 (Pubitemid 20055671)
31. Chiba T., Ezaki O., Dietary restriction suppresses inflammation and delays the onset of stroke in stroke-prone spontaneously hypertensive rats. Biochemical and Biophysical Research Communications 2010 399 1 98 103 2-s2.0-77955570393 10.1016/j.bbrc.2010.07.048
32. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C. U., Siler D. A., Arumugam T. V., Orthey E., Gerloff C., Tolosa E., Magnus T., Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009 40 5 1849 1857 2-s2.0-65549130913 10.1161/STROKEAHA.108.534503
33. Huang J., Upadhyay U. M., Tamargo R. J., Inflammation in stroke and focal cerebral ischemia. Surgical Neurology 2006 66 3 232 245 2-s2.0-33747781747 10.1016/j.surneu.2005.12.028 (Pubitemid 44279808)
34. Arumugam T. V., Granger D. N., Mattson M. P., Stroke and T-cells. NeuroMolecular Medicine 2005 7 3 229 242 2-s2.0-27144501850 10.1385/NMM:7:3:229 (Pubitemid 41507146)
35. Dahlöf B., Prevention of stroke in patients with hypertension. American Journal of Cardiology 2007 100 3, supplement S17 S24 10.1016/j.amjcard.2007.05.010 (Pubitemid 47103315)
36. Palmer A. J., Bulpitt C. J., Fletcher A. E., Beevers D. G., Coles E. C., Ledingham J. G. G., O'Riordan P. W., Petrie J. C., Rajagopalan B. E., Webster J., Dollery C. T., Relation between blood pressure and stroke mortality. Hypertension 1992 20 5 601 605 2-s2.0-0026739348
37. Marvar P. J., Lob H., Vinh A., Zarreen F., Harrison D. G., The central nervous system and inflammation in hypertension. Current Opinion in Pharmacology 2011 11 2 156 161 2-s2.0-79954421374 10.1016/j.coph.2010.12.001
38. Iadecola C., Davisson R. L., Hypertension and cerebrovascular dysfunction. Cell Metabolism 2008 7 6 476 484 2-s2.0-44349096287 10.1016/j.cmet.2008.03.010 (Pubitemid 351729202)
39. Pate M., Damarla V., Chi D. S., Negi S., Krishnaswamy G., Endothelial cell biology. Role in the inflammatory response. Advances in Clinical Chemistry 2010 52 109 130 2-s2.0-77957007533 10.1016/S0065-2423(10)52004-3
40. Wang H., Nawata J., Kakudo N., Sugimura K., Suzuki J., Sakuma M., Ikeda J., Shirato K., The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo. Journal of Hypertension 2004 22 7 1323 1332 2-s2.0-3042829252 10.1097/01.hjh.0000125437. 28861.40 (Pubitemid 38888078)
41. Lemarié C. A., Esposito B., Tedgui A., Lehoux S., Pressure-induced vascular activation of nuclear factor- B: role in cell survival. Circulation Research 2003 93 3 207 212 2-s2.0-0042025138 10.1161/01.RES.0000086942.13523.88 (Pubitemid 36993231)
42. Palomo I., Marín P., Alarcón M., Gubelin G., Viñambre X., Mora E., Icaza G., Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers. Clinical and Experimental Hypertension 2003 25 8 517 523 2-s2.0-0344464835 10.1081/CEH-120025335 (Pubitemid 37443139)
43. Liu Y., Liu T., McCarron R. M., Spatz M., Feuerstein G., Hallenbeck J. M., Sirén A. L., Evidence for activation of endothelium and monocytes in hypertensive rats. American Journal of Physiology 1996 270 6 H2125 H2131 2-s2.0-0029758127
44. Schmid-Schonbein G. W., Seiffge D., DeLano F. A., Shen K., Zweifach B. W., Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 1991 17 3 323 330 2-s2.0-0025968212
45. Clozel M., Kuhn H., Hefti F., Baumgartner H. R., Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition. Hypertension 1991 18 2 132 141 2-s2.0-0025894990
46. Dörffel Y., Lätsch C., Stuhlmüller B., Schreiber S., Scholze S., Burmester G. R., Scholze J., Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999 34 1 113 117 2-s2.0-2542509493 (Pubitemid 29325728)
47. Mervaala E. M. A., Müller D. N., Park J. K., Schmidt F., Löhn M., Breu V., Dragun D., Ganten D., Haller H., Luft F. C., Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999 33 1, part 2 389 395 2-s2.0-0345059270 (Pubitemid 29065690)
48. Theuer J., Dechend R., Muller D., Park J. K., Fiebeler A., Barta P., Ganten D., Haller H., Dietz R., Luft F. C., Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovascular Disorders 2002 2, article 3 2-s2.0-3042594445 10.1186/1475-2261-2-3 (Pubitemid 38824807)
49. Imakiire T., Kikuchi Y., Yamada M., Kushiyama T., Higashi K., Hyodo N., Yamamoto K., Oda T., Suzuki S., Miura S., Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis. Hypertension Research 2007 30 7 635 642 2-s2.0-34548039280 10.1291/hypres.30.635 (Pubitemid 47278322)
50. Saleh M. A., Boesen E. I., Pollock J. S., Savin V. J., Pollock D. M., Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010 56 5 942 949 2-s2.0-78149277201 10.1161/HYPERTENSIONAHA.110.156570
51. Das U. N., Is angiotensin-II an endogenous pro-inflammatory molecule? Medical Science Monitor 2005 11 5 RA155 RA162 2-s2.0-20344397446 (Pubitemid 40790953)
52. Vianna H. R., Soares C. M., Tavares M. S., Teixeira M. M., Silva A. C., Inflammation in chronic kidney disease: the role of cytokines. Jornal Brasileiro de Nefrologia 2011 33 3 351 364
53. Sironi L., Nobili E., Gianella A., Gelosa P., Tremoli E., Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs of Today 2005 41 9 609 622 2-s2.0-29144517417 10.1358/dot.2005.41.9.899613 (Pubitemid 41810476)
54. Okamoto K., Yamori Y., Nagaoka A., Establishment of the stroke prone spontaneously hypertensive rat (SHR). Circulation Research 1974 34 1 143 153 2-s2.0-0016222572
55. Sironi L., Guerrini U., Tremoli E., Miller I., Gelosa P., Lascialfari A., Zucca I., Eberini I., Gemeiner M., Paoletti R., Gianazza E., Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach. Journal of Neuroscience Research 2004 78 1 115 122 2-s2.0-4644306986 10.1002/jnr.20219 (Pubitemid 39305160)
56. Volpe M., Iaccarino G., Vecchione C., Rizzoni D., Russo R., Rubattu S., Condorelli G., Ganten U., Ganten D., Trimarco B., Lindpaintner K., Association and cosegregation of stroke with impaired endothelium- dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. The Journal of Clinical Investigation 1996 98 2 256 261 2-s2.0-9344221066 (Pubitemid 26255721)
57. Sironi L., Gianazza E., Gelosa P., Guerrini U., Nobili E., Gianella A., Cremonesi B., Paoletti R., Tremoli E., Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 3 598 603 2-s2.0-14644432487 10.1161/01.ATV.0000157145.98200.55 (Pubitemid 40315684)
58. Wilcox R., Bousser M. G., Betteridge D. J., Schernthaner G., Pirags V., Kupfer S., Dormandy J., Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 38 3 865 873 2-s2.0-33947539408 10.1161/01.STR.0000257974.06317.49 (Pubitemid 46568445)
59. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y. F., Matsuba S., Ogawa H., Kim-Mitsuyama S., Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007 38 11 3016 3022 2-s2.0-35748980879 10.1161/STROKEAHA.107.486522 (Pubitemid 350041562)
60. Ishizuka T., Niwa A., Tabuchi M., Ooshima K., Higashino H., Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats. Life Sciences 2008 82 13-14 806 815 2-s2.0-40649106179 10.1016/j.lfs.2008.01.017
61. Schroeter M., Jander S., Witte O. W., Stoll G., Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. Journal of Neuroimmunology 1994 55 2 195 203 2-s2.0-0028597088 10.1016/0165-5728(94)90010-8
62. Small D. L., Buchan A. M., Animal models. British Medical Bulletin 2000 56 2 307 317 2-s2.0-0033787214
63. Chen Y., Ito A., Takai K., Saito N., Blocking pterygopalatine arterial blood flow decreases infarct volume variability in a mouse model of intraluminal suture middle cerebral artery occlusion. Journal of Neuroscience Methods 2008 174 1 18 24 2-s2.0-49549096661 10.1016/j.jneumeth.2008.06.021
64. Tsuchiya D., Hong S., Kayama T., Panter S. S., Weinstein P. R., Effect of suture size and carotid clip application upon blood flow and infarct volume after permanent and temporary middle cerebral artery occlusion in mice. Brain Research 2003 970 1-2 131 139 2-s2.0-0037466463 10.1016/S0006-8993(03)02300-X (Pubitemid 36423188)
65. Beckmann N., High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magnetic Resonance in Medicine 2000 44 2 252 258 10.1002/1522- 2594(200008)44:2<252::AID-MRM12>3.0.CO;2-G (Pubitemid 30614784)
66. Barone F. C., Knudsen D. J., Nelson A. H., Feuerstein G. Z., Willette R. N., Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy. Journal of Cerebral Blood Flow and Metabolism 1993 13 4 683 692 2-s2.0-0027263342 (Pubitemid 23187512)
67. Dornas W. C., Silva M. E., Animal models for the study of arterial hypertension. Journal of Biosciences 2011 36 4 731 737 10.1007/s12038-011-9097-y
68. Nishijo N., Sugiyama F., Kimoto K., Taniguchi K., Murakami K., Suzuki S., Fukamizu A., Yagami K. I., Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Laboratory Investigation 1998 78 9 1059 1066 2-s2.0-0031661773 (Pubitemid 28440822)
69. Iida S., Baumbach G. L., Lavoie J. L., Faraci F. M., Sigmund C. D., Heistad D. D., Spontaneous stroke in a genetic model of hypertension in mice. Stroke 2005 36 6 1253 1258 2-s2.0-20444372244 10.1161/01.str.0000167694.58419.a2 (Pubitemid 40798748)
70. Shaftel S. S., Carlson T. J., Olschowka J. A., Kyrkanides S., Matousek S. B., O'Banion M. K., Chronic interleukin-1 β expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood-brain barrier permeability without overt neurodegeneration. Journal of Neuroscience 2007 27 35 9301 9309 2-s2.0-34548434392 10.1523/JNEUROSCI.1418-07.2007 (Pubitemid 47358197)
71. Boutin H., LeFeuvre R. A., Horai R., Asano M., Iwakura Y., Rothwell N. J., Role of IL-1 α and IL-1 β in ischemic brain damage. Journal of Neuroscience 2001 21 15 5528 5534 2-s2.0-0035413361 (Pubitemid 32692151)
72. Banwell V., Sena E. S., Macleod M. R., Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. Journal of Stroke and Cerebrovascular Diseases 2009 18 4 269 276 2-s2.0-67649117904 10.1016/j.jstrokecerebrovasdis.2008.11.009
73. Emsley H. C. A., Smith C. J., Georgiou R. F., Vail A., Hopkins S. J., Rothwell N. J., Tyrrell P. J., A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 10 1366 1372 2-s2.0-25444517949 10.1136/jnnp.2004.054882 (Pubitemid 41360973)
74. Rezaii A. A., Hoseinipanah S. M., Hajilooi M., Rafiei A. R., Shikh N., Haidari M., Interleukin-1 receptor antagonist gene polymorphism and susceptibility to ischemic stroke. Immunological Investigations 2009 38 3-4 220 230 2-s2.0-70350635584 10.1080/08820130902766142
75. Olsson S., Holmegaard L., Jood K., Sjögren M., Engström G., Lövkvist H., Blomstrand C., Norrving B., Lindgren A., Jern C., Genetic variation within the interleukin-1 gene cluster and ischemic stroke. Stroke 2012 43 9 2278 2282 10.1161/STROKEAHA.111.647446
76. Whiteley W., Jackson C., Lewis S., Lowe G., Rumley A., Sandercock P., Wardlaw J., Dennis M., Sudlow C., Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Medicine 2009 6 9 2-s2.0-70349636710 10.1371/journal.pmed.1000145 e1000145
77. Clark W. M., Rinker L. G., Lessov N. S., Hazel K., Hill J. K., Stenzel-Poore M., Eckenstein F., Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke 2000 31 7 1715 1720 2-s2.0-0033933545 (Pubitemid 30437528)
78. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S., The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta 2011 1813 5 878 888 2-s2.0-79955650634 10.1016/j.bbamcr.2011.01. 034
79. Zaremba J., Losy J., Early TNF- α levels correlate with ischaemic stroke severity. Acta Neurologica Scandinavica 2001 104 5 288 295 2-s2.0-0034771083 10.1034/j.1600-0404.2001.00053.x (Pubitemid 32977149)
80. Shohami E., Ginis I., Hallenbeck J. M., Dual role of tumor necrosis factor alpha in brain injury. Cytokine and Growth Factor Reviews 1999 10 2 119 130 2-s2.0-0032830106 10.1016/S1359-6101(99)00008-8 (Pubitemid 29446376)
81. Hallenbeck J. M., The many faces of tumor necrosis factor in stroke. Nature Medicine 2002 8 12 1363 1368 2-s2.0-0036908651 10.1038/nm1202-1363 (Pubitemid 36019420)
82. Nawashiro H., Martin D., Hallenbeck J. M., Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. Journal of Cerebral Blood Flow and Metabolism 1997 17 2 229 232 2-s2.0-0031051349 (Pubitemid 27085847)
83. Nawashiro H., Tasaki K., Ruetzler C. A., Hallenbeck J. M., TNF- α pretreatment induces protective effects against focal cerebral ischemia in mice. Journal of Cerebral Blood Flow and Metabolism 1997 17 5 483 490 2-s2.0-0031005797 (Pubitemid 27250974)
84. Banfi C., Sironi L., De Simoni G., Gelosa P., Barcella S., Perego C., Gianazza E., Guerrini U., Tremoli E., Mussoni L., Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats. Journal of Pharmacology and Experimental Therapeutics 2004 310 3 890 895 2-s2.0-4243141761 10.1124/jpet.104.067090 (Pubitemid 39108908)
85. Vakili A., Mojarrad S., Akhavan M. M., Rashidy-Pour A., Pentoxifylline attenuates TNF- α protein levels and brain edema following temporary focal cerebral ischemia in rats. Brain Research 2011 1377 119 125 2-s2.0-79951554006 10.1016/j.brainres.2011.01.001
86. Zaremba J., Ilkowski J., Losy J., Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke. Folia Neuropathologica 2006 44 4 282 289 2-s2.0-33846135757 (Pubitemid 46075787)
87. Hughes P. M., Allegrini P. R., Rudin M., Perry V. H., Mir A. K., Wiessner C., Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. Journal of Cerebral Blood Flow and Metabolism 2002 22 3 308 317 2-s2.0-0036194439 (Pubitemid 34203058)
88. Mathieu P., Poirier P., Pibarot P., Lemieux I., Després J. P., Visceral obesity the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009 53 4 577 584 2-s2.0-64849088450 10.1161/ HYPERTENSIONAHA.108.110320
89. Hall J. E., Da Silva A. A., Do Carmo J. M., Dubinion J., Hamza S., Munusamy S., Smith G., Stec D. E., Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. The Journal of Biological Chemistry 2010 285 23 17271 17276 2-s2.0-77952893301 10.1074/jbc.R110.113175
90. Yiannikouris F., Gupte M., Putnam K., Cassis L., Adipokines and blood pressure control. Current Opinion in Nephrology and Hypertension 2010 19 2 195 200 2-s2.0-76749144650 10.1097/MNH.0b013e3283366cd0
91. Weisberg S. P., McCann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W., Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 2003 112 12 1796 1808 2-s2.0-0348230958 10.1172/JCI200319246 (Pubitemid 38063703)
92. Bouloumié A., Curat C. A., Sengenès C., Lolmède K., Miranville A., Busse R., Role of macrophage tissue infiltration in metabolic diseases. Current Opinion in Clinical Nutrition and Metabolic Care 2005 8 4 347 354 (Pubitemid 40863045)
93. Kim B. J., Lee S.-H., Ryu W.-S., Kim C. K., Yoon B.-W., Adipocytokines and ischemic stroke: differential associations between stroke subtypes. Journal of the Neurological Sciences 2012 312 1-2 117 122 10.1016/j.jns.2011.08.007
94. Gerdes S., Osadtschy S., Rostami-Yazdi M., Buhles N., Weichenthal M., Mrowietz U., Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis? Experimental Dermatology 2012 21 1 43 47 10.1111/j.1600-0625.2011.01402.x
95. Prugger C., Luc G., Haas B., Arveiler D., MacHez E., Ferrieres J., Ruidavets J.-B., Bingham A., Montaye M., Amouyel P., Yarnell J., Kee F., Ducimetiere P., Empana J.-P., Adipocytokines and the risk of ischemic stroke: the PRIME Study. Annals of Neurology 2012 71 4 478 486 10.1002/ana.22669
96. Söderberg S., Colquhoun D., Keech A., Yallop J., Barnes E. H., Pollicino C., Simes J., Tonkin A. M., Nestel P., Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. International Journal of Obesity 2009 33 1 123 130 2-s2.0-58149484949 10.1038/ijo.2008.224
97. Yamagishi S. I., Edelstein D., Du X. L., Kaneda Y., Guzmán M., Brownlee M., Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. The Journal of Biological Chemistry 2001 276 27 25096 25100 2-s2.0-0035816639 10.1074/jbc.M007383200
98. Loffreda S., Yang S. Q., Lin H. Z., Karp C. L., Brengman M. L., Wang D. J., Klein A. S., Bulkley G. B., Bao C., Noble P. W., Lane M. D., Diehl A. M., Leptin regulates proinflammatory immune responses. The FASEB Journal 1998 12 1 57 65 2-s2.0-0031965266 (Pubitemid 28060271)
99. Folco E. J., Rocha V. Z., López-Ilasaca M., Libby P., Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. The Journal of Biological Chemistry 2009 284 38 25569 25575 2-s2.0-70350036010 10.1074/jbc.M109.019786
100. Ohashi K., Parker J. L., Ouchi N., Higuchi A., Vita J. A., Gokce N., Pedersen A. A., Kalthoff C., Tullin S., Sams A., Summer R., Walsh K., Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. The Journal of Biological Chemistry 2010 285 9 6153 6160 2-s2.0-77949881805 10.1074/jbc.M109.088708
101. Kumada M., Kihara S., Ouchi N., Kobayashi H., Okamoto Y., Ohashi K., Maeda K., Nagaretani H., Kishida K., Maeda N., Nagasawa A., Funahashi T., Matsuzawa Y., Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004 109 17 2046 2049 2-s2.0-2442464884 10.1161/01.CIR.0000127953. 98131.ED (Pubitemid 38620209)
102. Thundyil J., Pavlovski D., Sobey C. G., Arumugam T. V., Adiponectin receptor signalling in the brain. British Journal of Pharmacology 2012 165 2 313 327
103. Friedman J. M., Leptin, leptin receptors and the control of body weight. European Journal of Medical Research 1997 2 1 7 13 2-s2.0-0030639578
104. Ridker P. M., Danielson E., Fonseca F. A. H., Genest J., Gotto A. M., Kastelein J. J. P., Koenig W., Libby P., Lorenzatti A. J., MacFadyen J. G., Nordestgaard B. G., Shepherd J., Willerson J. T., Glynn R. J., Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 359 21 2195 2207 2-s2.0-56749106312 10.1056/NEJMoa0807646
105. Amarenco P., Labreuche J., Lavallée P., Touboul P. J., Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004 35 12 2902 2909 2-s2.0-9444249842 10.1161/01.STR.0000147965.52712.fa (Pubitemid 39565192)
106. Liao J. K., Beyond lipid lowering: the role of statins in vascular protection. International Journal of Cardiology 2002 86 1 5 18 2-s2.0-0036829777 10.1016/S0167-5273(02)00195-X (Pubitemid 35247880)
107. Vaughan C. J., Prevention of stroke and dementia with statins: effects beyond lipid lowering. American Journal of Cardiology 2003 91 4, supplement 23 29 2-s2.0-0037456569 10.1016/S0002-9149(02)03270-8 (Pubitemid 36263245)
108. Vergouwen M. D. I., De Haan R. J., Vermeulen M., Roos Y. B. W. E. M., Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 2008 39 2 497 502 2-s2.0-39349084356 10.1161/STROKEAHA.107.488791 (Pubitemid 351619482)
109. Puddey I. B., Low serum cholesterol and the risk of cerebral haemorrhage. Atherosclerosis 1996 119 1 1 6 2-s2.0-0030050630 10.1016/0021-9150(95)05634-3 (Pubitemid 26018752)
110. White A. T., Murphy A. N., Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. Journal of Neurochemistry 2010 115 4 845 853 2-s2.0-77958610176 10.1111/j.1471-4159.2010. 06999.x
111. Zhao X., Grotta J., Gonzales N., Aronowski J., Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke 2009 40 3 S92 S94 2-s2.0-62949163677 10.1161/STROKEAHA.108.533158
112. Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefèbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Korányi L., Laakso M., Mokáň M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Škrha J., Smith U., Tatoň J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. The Lancet 2005 366 9493 1279 1289 2-s2.0-26244453309 10.1016/S0140-6736(05)67528-9 (Pubitemid 41416583)
113. Graham D. J., Ouellet-Hellstrom R., Macurdy T. E., Ali F., Sholley C., Worrall C., Kelman J. A., Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010 304 4 411 418 2-s2.0-77954988618 10.1001/jama.2010.920
114. Buring J. E., A perspective on the women's healthy study: aspirin prevents stroke but not MI in Women; Vitamin E has no effect on CV disease or cancer. Cleveland Clinic Journal of Medicine 2006 73 9 863 870 2-s2.0-33748643211 10.3949/ccjm.73.9.863 (Pubitemid 44383239)
115. Tymianski M., Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke 2011 42 11 3003 3004 10.1161/STROKEAHA.111. 626762
116. Gelosa P., Ballerio R., Banfi C., Nobili E., Gianella A., Pignieri A., Brioschi M., Guerrini U., Castiglioni L., Blanc-Guillemaud V., Lerond L., Tremoli E., Sironi L., Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. Journal of Pharmacology and Experimental Therapeutics 2010 334 1 199 205 2-s2.0-77953738863 10.1124/jpet.110.165787
117. Bousser M. G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K., Hennerici M. G., Mattle H. P., Rothwell P. M., Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases 2009 27 5 509 518 2-s2.0-64549164466 10.1159/000212671
118. Bousser M. G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K. M., Hennerici M. G., Mattle H. P., Rothwell P. M., De Cordoüe A., Fratacci M. D., Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. The Lancet 2011 377 9782 2013 2022 2-s2.0-79958770159 10.1016/S0140-6736(11)60600-4
119. Kitamura Y., Yanagisawa D., Inden M., Takata K., Tsuchiya D., Kawasaki T., Taniguchi T., Shimohama S., Recovery of focal brain ischemia-induced behavioral dysfunction by intracerebroventricular injection of microglia. Journal of Pharmacological Sciences 2005 97 2 289 293 2-s2.0-15744362925 10.1254/jphs.SC0040129 (Pubitemid 40410270)
120. Kitamura Y., Takata K., Inden M., Tsuchiya D., Yanagisawa D., Nakata J., Taniguchi T., Intracerebroventricular injection of microglia protects against focal brain ischemia. Journal of Pharmacological Sciences 2004 94 2 203 206 2-s2.0-1642504310 10.1254/jphs.94.203 (Pubitemid 38405136)
121. Batchelor P. E., Liberatore G. T., Wong J. Y. F., Porritt M. J., Frerichs F., Donnan G. A., Howells D. W., Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Journal of Neuroscience 1999 19 5 1708 1716 2-s2.0-0033104019 (Pubitemid 29094189)
122. Nakajima K., Kohsaka S., Microglia: neuroprotective and neurotrophic cells in the central nervous system. Current Drug Targets 2004 4 1 65 84 2-s2.0-1642442424 10.2174/1568006043481284 (Pubitemid 38404716)
123. O'Donnell S. L., Frederick T. J., Krady J. K., Vannucci S. J., Wood T. L., IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. GLIA 2002 39 1 85 97 2-s2.0-0036628509 10.1002/glia.10081
124. LaThe Lancette-Hébert M., Gowing G., Simard A., Yuan C. W., Kriz J., Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. Journal of Neuroscience 2007 27 10 2596 2605 2-s2.0-33847785649 10.1523/JNEUROSCI.5360-06.2007 (Pubitemid 46393607)
125. Hanisch U. K., Kettenmann H., Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nature Neuroscience 2007 10 11 1387 1394 2-s2.0-35548986304 10.1038/nn1997 (Pubitemid 350014685)
126. Ohtaki H., Ylostalo J. H., Foraker J. E., Robinson A. P., Reger R. L., Shioda S., Prockop D. J., Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proceedings of the National Academy of Sciences of the United States of America 2008 105 38 14638 14643 2-s2.0-55749098498 10.1073/pnas.0803670105
127. Gibson C. L., Coughlan T. C., Murphy S. P., Glial nitric oxide and ischemia. GLIA 2005 50 4 417 426 2-s2.0-20344392918 10.1002/glia.20143 (Pubitemid 40780845)
128. Hattori H., Suzuki S., Okazaki Y., Suzuki N., Kuwana M., Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats. Journal of Neuroscience Research 2012 90 2 479 488 10.1002/jnr.22755